American Society of Hematology Conference Features Exciting MPN Updates Including MPNRF Funded Research Normally the annual meeting of the American Society of Hematology (commonly referred… Read More »ASH CONFERENCE FEATURES EXCITING MPN UPDATES INCLUDING MPNRF FUNDED RESEARCH
April 12, 2019 After completing a number of clinical trials, The MPN community was disappointed when a promising compound in development for myelofibrosis, momelotinib, was… Read More »PROMISING MF TREATMENT, MOMELOTINIB, IN DEVELOPMENT ONCE MORE
You may have heard that MPNRF, along with fellow MPN advocates, is holding an externally-led Patient Focused Drug Development meeting with the FDA this September. If you are… Read More »LET THE FDA KNOW ABOUT YOUR EXPERIENCE LIVING WITH PV, ET OR MF!
BLOOD ARTICLE DISCUSSES EPIGENETIC CHANGES IN MYELOFIBROSIS FOLLOWING DISCONTINUATION OF RUXOLITINIB
The MPN community is discussing the article by MPN researchers from MD Anderson – Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation – a retrospective study… Read More »BLOOD ARTICLE DISCUSSES EPIGENETIC CHANGES IN MYELOFIBROSIS FOLLOWING DISCONTINUATION OF RUXOLITINIB
I was hired by the MPN Research Foundation in May 2016 to spearhead the development and launch of the first ever patient driven registry. At… Read More »HOW WE CAN HELP MOVE MPN RESEARCH FORWARD TOGETHER
The Centers for Medicare & Medicaid Services’ Coverage and Analysis Group released a proposed decision memo Thursday on modifications to the National Coverage Determination for… Read More »UPDATE ON MEDICARE COVERAGE DECISION FOR STEM CELL TRANSPLANT IN MYELOFIBROSIS
Does the smiling face of Layla Richards mark a new era in genetic medicine that could change all our lives? The story of Layla Richards… Read More »IS THIS THE BEGINNING OF GENE-EDITING MEDICINE?